| Rheumatoid Arthritis

Simponi vs Vimovo

Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.
Deep comparison between: Simponi vs Vimovo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsVimovo has a higher rate of injection site reactions vs Simponi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vimovo but not Simponi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Simponi
Vimovo
At A Glance
SC injection
Every 4 weeks
TNF-alpha inhibitor
Oral
Twice daily
NSAID + Proton Pump Inhibitor
Indications
  • Rheumatoid Arthritis
  • Arthritis, Psoriatic
  • Ankylosing spondylitis
  • Ulcerative Colitis
  • Degenerative polyarthritis
  • Rheumatoid Arthritis
  • Ankylosing spondylitis
  • Juvenile arthritis
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 50 mg SC once a month.
Ulcerative Colitis (adults and pediatric patients >=40 kg) 200 mg SC at Week 0, 100 mg at Week 2, then 100 mg every 4 weeks.
Ulcerative Colitis (pediatric patients >=15 kg to <40 kg) 100 mg SC at Week 0, 50 mg at Week 2, then 50 mg every 4 weeks.
Degenerative polyarthritis, Rheumatoid Arthritis, Ankylosing spondylitis Adults: one tablet (375 mg or 500 mg naproxen/20 mg esomeprazole) twice daily, taken orally at least 30 minutes before meals; use lowest effective naproxen dose for shortest duration.
Juvenile arthritis Adolescents >=12 years and >50 kg: one tablet (375 mg or 500 mg naproxen/20 mg esomeprazole) twice daily; 38 kg to <50 kg: one tablet (375 mg naproxen/20 mg esomeprazole) twice daily, taken at least 30 minutes before meals.
Contraindications
—
  • Known hypersensitivity to naproxen, esomeprazole magnesium, substituted benzimidazoles, or any components of the drug product, including omeprazole
  • History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
  • Coronary artery bypass graft (CABG) surgery
  • Concomitant use of rilpivirine-containing products
Adverse Reactions
Most common (>=1%) Upper respiratory tract infection, viral infections, bronchitis, superficial fungal infections, sinusitis, injection site reaction, alanine aminotransferase increased, aspartate aminotransferase increased, hypertension, dizziness, paresthesia, constipation
Serious Serious infections, malignancies, congestive heart failure, demyelinating disorders, hepatitis B reactivation, autoimmunity, hematologic cytopenias, hypersensitivity reactions
Postmarketing Serious systemic hypersensitivity reactions, sarcoidosis, melanoma, Merkel cell carcinoma, interstitial lung disease, skin exfoliation, lichenoid reactions, rash, bullous skin reactions
Most common (>2%) Gastritis, diarrhea, upper respiratory tract infection, flatulence, headache, urinary tract infection, dysgeusia
Serious Cardiovascular thrombotic events, GI bleeding/ulceration/perforation, hepatotoxicity, hypertension, heart failure and edema, renal toxicity and hyperkalemia, anaphylactic reactions, serious skin reactions, DRESS, fetal toxicity, hematologic toxicity
Postmarketing Gait disturbance, abdominal distension, hematochezia, joint swelling, muscle spasms, renal tubular necrosis, angioedema, aplastic anemia, hepatitis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, hypomagnesemia, cutaneous lupus erythematosus
Pharmacology
Golimumab is a human IgG1 monoclonal antibody (TNF-alpha inhibitor) that binds to both the soluble and transmembrane bioactive forms of human TNF-alpha, preventing its binding to receptors and inhibiting the biological activity of TNF-alpha in inflammatory diseases.
VIMOVO is a fixed-dose combination of naproxen, an NSAID that inhibits cyclooxygenase (COX-1 and COX-2) to reduce prostaglandin synthesis with analgesic, anti-inflammatory, and antipyretic effects, and esomeprazole magnesium, a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase in the gastric parietal cell to reduce naproxen-associated gastric ulcer risk.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Simponi
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
View full coverage details ›
Vimovo
  • Covered on 5 commercial plans
  • PA (6/12) · Step Therapy (1/12) · Qty limit (1/12)
View full coverage details ›
UnitedHealthcare
Simponi
  • Covered on 4 commercial plans
  • PA (8/8) · Step Therapy (7/8) · Qty limit (7/8)
View full coverage details ›
Vimovo
  • Covered on 4 commercial plans
  • PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
View full coverage details ›
Humana
Simponi
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
View full coverage details ›
Vimovo
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Simponi.
No savings programs available for Vimovo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
SimponiView full Simponi profile
VimovoView full Vimovo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.